Anti-EPAC1 Antibody
- 产品详情
- 实验流程
Application
| WB, IHC |
|---|---|
| Primary Accession | O95398 |
| Reactivity | Human, Mouse, Rat, Bovine, Dog |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 103751 Da |
| Gene ID | 10411 |
|---|---|
| Other Names | CGEF1; EPAC; EPAC1; Rap guanine nucleotide exchange factor 3; Exchange factor directly activated by cAMP 1; Exchange protein directly activated by cAMP 1; EPAC 1; Rap1 guanine-nucleotide-exchange factor directly activated by cAMP; cAMP-regulated guanine nucleotide exchange factor I; cAMP-GEFI |
| Target/Specificity | KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human EPAC1. The exact sequence is proprietary. |
| Dilution | WB~~WB (1/500 - 1/1000) IHC~~1:100~500 |
| Format | Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. |
| Storage | Store at -20 °C.Stable for 12 months from date of receipt |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | RAPGEF3 |
|---|---|
| Synonyms | CGEF1, EPAC, EPAC1 |
| Function | Guanine nucleotide exchange factor (GEF) for RAP1A and RAP2A small GTPases that is activated by binding cAMP. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which it activates the PI3K gamma complex and which is involved in angiogenesis. Plays a role in the modulation of the cAMP- induced dynamic control of endothelial barrier function through a pathway that is independent on Rho-mediated signaling. Required for the actin rearrangement at cell-cell junctions, such as stress fibers and junctional actin. |
| Cellular Location | Endomembrane system |
| Tissue Location | Widely expressed with highest levels in adult kidney, heart, thyroid and brain, and fetal kidney |
Research Areas
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
REFERENCES
Kawasaki H.,et al.Science 282:2275-2279(1998).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Scherer S.E.,et al.Nature 440:346-351(2006).
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
de Rooij J.,et al.Nature 396:474-477(1998).
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
¥ 1,250.00
Cat# AP51831
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。